Nasdaq · Healthcare
EyePoint, Inc. (EYPT)
As-reported financials and recent SEC filings for EyePoint, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$31.4M
Net income
$-232.0M
Net margin
—
Diluted EPS
$-3.17
ROE
-75.8%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $31.4M | $43.3M | $46.0M | $41.4M | $36.9M |
| Gross profit | — | — | — | — | — |
| Operating income | $-243.4M | $-145.9M | $-75.1M | $-99.6M | $-55.3M |
| Net income | $-232.0M | $-130.9M | $-70.8M | $-102.3M | $-58.4M |
| Diluted EPS | $-3.17 | $-2.32 | $-1.82 | $-2627.66 | $-1946.77 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-02
View on EDGAR →8-K2026-06-22
View on EDGAR →SCHEDULE 13G2026-06-03
View on EDGAR →42026-05-27
View on EDGAR →SCHEDULE 13G/A2026-05-15
View on EDGAR →8-K2026-05-14
View on EDGAR →SCHEDULE 13G/A2026-05-13
View on EDGAR →10-Q2026-05-07
View on EDGAR →Largest Healthcare peers
Go deeper on EYPT
Search EyePoint, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.